|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0021308,
umls-concept:C0021701,
umls-concept:C0030705,
umls-concept:C0054942,
umls-concept:C0064830,
umls-concept:C0155626,
umls-concept:C0162577,
umls-concept:C0332206,
umls-concept:C0332293,
umls-concept:C0439851,
umls-concept:C0456389,
umls-concept:C0597357,
umls-concept:C1274040,
umls-concept:C1280500,
umls-concept:C1552596,
umls-concept:C1947931,
umls-concept:C2603343
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2002-10-17
|
|
pubmed:abstractText |
The purpose of this study was to determine whether Hu23F2G (LeukoArrest), an antibody to the CD11/CD18 integrin receptors, would reduce infarct size in patients undergoing primary angioplasty for an acute myocardial infarction.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD11,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD18,
http://linkedlifedata.com/resource/pubmed/chemical/HU23F2G,
http://linkedlifedata.com/resource/pubmed/chemical/Integrins,
http://linkedlifedata.com/resource/pubmed/chemical/Radiopharmaceuticals,
http://linkedlifedata.com/resource/pubmed/chemical/Technetium Tc 99m Sestamibi
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0735-1097
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
2
|
|
pubmed:volume |
40
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1199-204
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12383565-Angioplasty, Balloon, Coronary,
pubmed-meshheading:12383565-Antibodies, Monoclonal,
pubmed-meshheading:12383565-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:12383565-Antigens, CD11,
pubmed-meshheading:12383565-Antigens, CD18,
pubmed-meshheading:12383565-Combined Modality Therapy,
pubmed-meshheading:12383565-Coronary Angiography,
pubmed-meshheading:12383565-Double-Blind Method,
pubmed-meshheading:12383565-Electrocardiography,
pubmed-meshheading:12383565-Female,
pubmed-meshheading:12383565-Humans,
pubmed-meshheading:12383565-Integrins,
pubmed-meshheading:12383565-Male,
pubmed-meshheading:12383565-Middle Aged,
pubmed-meshheading:12383565-Myocardial Infarction,
pubmed-meshheading:12383565-Proportional Hazards Models,
pubmed-meshheading:12383565-Radiopharmaceuticals,
pubmed-meshheading:12383565-Survival Analysis,
pubmed-meshheading:12383565-Technetium Tc 99m Sestamibi,
pubmed-meshheading:12383565-Time Factors,
pubmed-meshheading:12383565-Tomography, Emission-Computed, Single-Photon,
pubmed-meshheading:12383565-Treatment Outcome
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study.
|
|
pubmed:affiliation |
Los Angeles County Medical Center and the University of Southern California School of Medicine, Los Angeles, California 60637, USA. dfaxon@medicine.bsd.uchicago.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
